ConvaTec Group/£CTEC
1D1W1MYTD1Y5YMAX
Capital at risk
About ConvaTec Group
- Ticker
- £CTEC
- Sector
- Health
- Primary listing
- LSE
- Employees
- 10,000
- Headquarters
- London, United Kingdom
- Website
- www.convatecgroup.com
ConvaTec Group Metrics
BasicAdvanced
£4.3B
47.79
£0.05
0.76
£0.05
2.45%
Price and volume
Market cap
£4.3B
Beta
0.76
52-week high
£2.59
52-week low
£1.93
Average daily volume
7.7M
Dividend rate
£0.05
Financial strength
Current ratio
1.932
Quick ratio
1.064
Long term debt to equity
1.201
Total debt to equity
1.218
Dividend payout ratio (TTM)
115.32%
Interest coverage (TTM)
6.06%
Profitability
EBITDA (TTM)
431.582
Gross margin (TTM)
56.00%
Net profit margin (TTM)
4.98%
Operating margin (TTM)
16.30%
Effective tax rate (TTM)
22.50%
Revenue per employee (TTM)
£185,380
Management effectiveness
Return on assets (TTM)
6.72%
Return on equity (TTM)
7.65%
Valuation
Price to earnings (TTM)
47.788
Price to revenue (TTM)
2.353
Price to book
2.99
Price to tangible book (TTM)
-9.22
Price to free cash flow (TTM)
40.71
Free cash flow yield (TTM)
2.46%
Free cash flow per share (TTM)
0.054
Dividend yield (TTM)
2.45%
Growth
Revenue change (TTM)
5.75%
Earnings per share change (TTM)
-41.54%
3-year revenue growth (CAGR)
6.14%
10-year revenue growth (CAGR)
4.04%
3-year earnings per share growth (CAGR)
22.06%
10-year earnings per share growth (CAGR)
-7.28%
3-year dividend per share growth (CAGR)
7.05%
What the Analysts think about ConvaTec Group
Analyst ratings (Buy, Hold, Sell) for ConvaTec Group stock.
Analyst projections of the future price of ConvaTec Group stock.
Bulls say / Bears say
Delivered 5.0% organic revenue growth ex-InnovaMatrix in H1 2026, driven by broad-based gains across advanced wound care, ostomy, continence, and infusion care segments (Reuters)
Achieved an adjusted operating margin of 21.2% in H1 2026 (up 50 basis points in constant currency), on track to meet or exceed the ≥23.0% target for FY 2026 through simplification and productivity initiatives (Reuters)
Announced a $200 million share buyback programme to be completed by end-2026, signalling strong free-cash-flow generation and commitment to shareholder returns (Reuters)
InnovaMatrix revenue plunged over 90% following US reimbursement changes, triggering a $69 million non-cash impairment and contributing to a 36.1% decline in reported operating profit in H1 2026 (Reuters)
Convatec warned in May that higher raw material costs linked to the Iran conflict could weigh on 2027 margins, highlighting emerging inflationary pressure on production expenses (Reuters)
Full-year adjusted operating margin guidance factors in a c.40 basis-point FX headwind, underscoring the company’s vulnerability to currency fluctuations between the US dollar and pound sterling (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
ConvaTec Group Financial Performance
Revenues and expenses
ConvaTec Group Earnings Performance
Company profitability
Upcoming events
Funds containing ConvaTec Group
AllEURGBPUSD
Fund name | Fund size | £CTEC weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.32% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.32% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.32% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.32% |
iShares Core FTSE 100€ISFA | €19B | 0.17% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.